Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > August 1, 2024
Daily News
August 1, 2024
- Nitrosamine Self-Inspection Deadline Extended to Aug. 1 amid Challenges
August 1, 2024
- Toa Eiyo to Downsize Workforce by 100 through Voluntary Buyout
August 1, 2024
- Sumitomo Announces Its Largest-Yet Job Cut of 700 Employees in Japan
August 1, 2024
- Prevenar 20 to Join National Immunization for Children from October
August 1, 2024
- SanBio’s Cell Therapy Akuugo Scores Conditional Approval
August 1, 2024
- Daiichi Sankyo’s Q1 Sales Grow 24% as Mainstays Fare Well
August 1, 2024
- Chugai to Develop Roche’s PI3K Inhibitor Inavolisib in Japan
August 1, 2024
- AstraZeneca Files Tagrisso, Imfinzi for Post-Chemoradiation Setting
August 1, 2024
- Japan’s Generic Use Rate at 82.7% in FY2023: JGA
August 1, 2024
- Twymeeg Champion Trophy Winner in June GP Rep Promotion Rankings: Intage
August 1, 2024
Japan’s pharmaceutical industry has become a global business over the past two decades. Overseas markets now make up nearly three-quarters…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…